September 04, 2020
1 min read
Save

LumiThera receives NEI grant in support of clinical trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LumiThera Inc. is the recipient of a $1.5 million grant from the National Eye Institute in support of a clinical trial investigating a new treatment for diabetes-related ocular pathology, according to a press release.

The grant supports the photobiomodulation reduction in macular edema, or PRIME, trial. The trial is a prospective, randomized, multicenter trial investigating the effects of the Valeda light delivery system in patients with diabetic retinopathy and diabetic macular edema. The trial is subject to FDA investigational device exemption approval.

"We will be evaluating if PBM can provide an early treatment for DR and reduce macular edema. If successful, PBM could delay or reduce the need for intravitreal pharmacotherapy with currently approved anti-VEGF medications or replace invasive laser surgery," Quan Dong Nguyen, MD, MSc, and Diana V. Do, MD, said in the release.